Dendrite Holds Annual Analyst and Investor Conference.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Sept. 14, 2000

Details Current Financial Performance;

Sustaining Growth;

Financial Model Update;

Updated Outlook for Last Half 2000 and Full Year 2001

Dendrite International, Inc., the leading provider of sales and marketing effectiveness solutions for the pharmaceutical industry (NASDAQ/NMS:DRTE) held its annual analyst and investor conference today where they provided updates to financial guidance and reviewed market performance and new product releases including the launch of several new data initiatives.

With over 100 analysts and investors in attendance, Chairman and CEO, John Bailye, opened the conference with a discussion of industry trends and the resulting opportunities that are being created for Dendrite. Mr. Bailye highlighted several new product and service offerings. A new organization structure designed to support strengthening growth anticipated by these strategic initiatives was also announced.

George Robson, Executive VP and CFO followed Mr. Bailye's presentation with an analysis of Dendrite's recent outstanding performance. He described a new facility expansion planned for April 2001 that will absorb some of the significant growth Dendrite is achieving. Mr. Robson also described a new technology access-licensing model that will be offered to the very largest prospective customers of Dendrite to further Dendrite's Global Reach Strategy. This model is expected to further enhance revenue predictably as well as increase overall total revenue as each new Technology Access Agreement is deployed.

Discussing financial results, Mr. Robson stated that the Company was currently comfortable with current 2000 full year revenue estimates, but indicated that some third quarter new business opportunities may conclude later than originally projected.

George Robson added, "Dendrite continues to have a path to work its way toward the range that analysts are estimating for third quarter revenue. As usual, there is still selling to be done." The company indicated that anywhere in the expected third quarter revenue range is expected to create earnings consistent with current estimates.

The Company also indicated there could be a modest upside to EPS in the fourth quarter of 1 cent - 2 cents.

The Company indicated that 2001 growth could be even higher than this years, reaching 28%-30%. "If we do really well in a couple of situations, our growth could be above the 28-30% growth goal, but we won't count on it until its won," said Mr. Robson. Operating margins should continue to increase next year, but given the investments in expanded management and facilities that have been announced, the increase will be moderate. Below the operating profit line, interest income shouldn't increase a great deal since the Company will be using its own cash for the capital requirements at its new site.

Mr. Robson also estimated a slightly increased tax rate for fiscal 2001 if the Company exceeds targets. Rather than maintain a 36% rate, the tax rate could increase to 36-1/2% or 37% in 2001, and is likely to go up to this rate in fiscal 2002 if it doesn't occur in fiscal 2001. And finally, the Company is continuing its goal of keeping DSO below 65 days with consideration given for the seasonal pattern whereby 1st quarter DSO rises from year-end levels.

ABOUT DENDRITE

Dendrite International, Inc (NASDAQ/NMS:DRTE) supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986. Headquartered in Morristown, New Jersey, Dendrite employs over 1400 people around the world. For more information, including information on upcoming financial events, visit the Company's Web site at http://www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) timing of revenue recognition is dependent on many factors including timing of customer acceptance of product offerings and execution of contracts for Dendrite products, which factors are often outside the Company's control and which cannot always be predicted (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.